Objective: To identify clinical hallmarks associated with recovery of gastrointestinal transit. Background: Impaired gastrointestinal transit or postoperative ileus largely determines clinical recovery after abdominal surgery. However, validated clinical hallmarks of gastrointestinal recovery to evaluate new treatments and readiness for discharge from the hospital are lacking. Methods: Gastric emptying and colonic transit were scintigraphically assessed from postoperative day 1 to 3 in 84 patients requiring elective colonic surgery and were compared with clinical parameters. The clinical hallmark that best reflected recovery of gastrointestinal transit was validated using data from a multicenter trial of 320 segmental colectomy patients. Results: Seven of 84 patients developed a major complication with paralytic ileus characterized by total inhibition of gastrointestinal motility and were excluded from further analysis. In the remaining patients, recovery of colonic transit (defined as geometric center of radioactivity ≥2 on day 3), but not gastric emptying, was significantly correlated with clinical recovery (ρ = −0.59, P < 0.001). Conversely, the combined outcome measure of tolerance of solid food and having had defecation (SF + D) (area under the curve = 0.9, SE = 0.04, 95% CI = 0.79-0.95, P < 0.001), but not time to first flatus, best indicated recovery of gastrointestinal transit with a positive predictive value of 93% (95% CI = 78-99). Also in the main clinical trial, multiple regression analysis revealed that SF + D best predicted the duration of hospital stay. Conclusions: Our data indicate that the time to SF + D best reflects recovery of gastrointestinal transit and therefore should be considered as primary outcome measure in future clinical trials on postoperative ileus.
postoperative ileus (POI). POI largely determines clinical recovery and hospital stay after abdominal surgery, 1-3 thereby significantly contributing to postoperative morbidity and hospitalization costs. 1, 2 Postoperative inhibition of GI motility results in impaired intestinal transit and stasis of intraluminal contents, leading to symptoms and signs such as nausea, vomiting, bloating, delayed passage of flatus and stool, and the inability to tolerate solid food. 4, 5 As improvement of these parameters is believed to represent recovery of GI transit and resolution of POI, especially time to return of bowel sounds, first flatus and defecation are often used as primary and/or secondary outcome measures in clinical trials. 1, 6 It should be emphasized though that these parameters are difficult to assess accurately. Moreover, passing stool or flatus may rather mirror rectal emptying and therefore not necessarily adequately reflect recovery of effective GI motility. Therefore, it is of great importance for future studies to determine the relationship between objectively demonstrated recovery of GI transit and clinical parameters to identify potential clinical outcome measures. Subsequently, these parameters should be validated in a separate cohort before accepting one of these as outcome measure in future clinical trials.
Scintigraphic recording of GI transit is considered the criterion standard to assess GI motility. This technique allows accurate evaluation of motility throughout the entire GI tract in a safe and noninvasive way. [7] [8] [9] It has been successfully used to evaluate pharmacological interventions in healthy subjects and patients with colonic motility disorders. [9] [10] [11] In the current study, we used this technique to study the relationship between GI transit and clinical symptoms to identify the most reliable clinical markers of bowel function recovery.
METHODS

Study I: Identification of clinical outcome measures for recovery of transit based on scintigraphic assessment Patients
This study was performed at the Academic Medical Center of Amsterdam. Patients enrolled in the LAFA (LAparoscopy and/or Fast-track multimodal management vs standard care) multicenter trial were eligible for this study. 12 Between 2005 and 2009, patients were invited to participate if they were to undergo elective segmental colectomy for colonic cancer without evidence of metastatic disease. This study is registered with Netherlands National Trial Register, number NTR1884. The study was conducted in accordance with the principles of the Declaration of Helsinki. The protocol was approved by the Medical Ethics Review Board of the Academic Medical Center in Amsterdam (The Netherlands). patients underwent a solid gastric emptying test [technetium-99 ( 99m Tc)-labeled pancake] directly followed by the ingestion of 60 mL of indium-111 ( 111 In)-labeled water to assess colonic transit on postoperative day 2 and day 3 as previously described. 3 Calculation of gastric retention and colonic transit was performed blinded by 2 researchers independently (S.v.B. and R.J.B.) on a Hermes workstation. In addition, clinical signs and symptoms of upper and lower GI motility were assessed on a daily basis by a trial nurse and/or a research physician using a standardized questionnaire ( Fig. 1A) . Patients were assisted to fill in this self-assessment sheet daily from the time of scintigraphy until discharge. Times to first occurrence of these events (passing flatus, passing stool, bowel sounds, and consumption of solid food) and time to discharge were recorded. In addition, nursing staff reported daily on the patient's progress-that is, food intake, passage of flatus and stool-and predefined discharge criteria were checked. The time until ready for discharge was defined as the time until a patient was without complications, tolerated solid food, and pain was adequately controlled with oral analgetics. Time to tolerance of solid food was defined as the time to solid food intake with no significant nausea or vomiting. Clinical parameter assessments were obtained daily by the principal investigators via interviewing the patients, followed by chart review. 13 The time to the clinical end points (eg, toleration of solid food, defecation, and flatus) were measured in hours, starting at completion of abdominal incision closure. A patient was considered to have met the endpoint when (s)he had first tolerated solid food and either passed flatus or experienced his/her first bowel movement. All patients were discharged according to the same predefined discharge criteria as patients from the LAFA multicenter trial, that is, the 9-center randomized trial comparing fast-track or standard care in patients undergoing conventional and laparoscopic segmental resection for colon cancer (registration NTR number: NTR222).
FIGURE 1.
A, Study protocol. Twenty-four hours after surgery, patients underwent a solid gastric emptying test ( 99m Tc-labeled pancake) directly followed by the ingestion of 60 mL of 111 In-DTPA-labeled water to assess colonic transit on postoperative day 2 and day 3. In addition, clinical signs and symptoms were assessed on a daily basis using a symptom questionnaire (Q). B, Time until ready for discharge versus colonic transit on day 2 and day 3. Median time until ready for discharge versus colonic transit on day 2 (n = 77) and day 3 (n = 76). Data are shown as median, IQR.
In this trial, patients were discharged if they complied with the following predefined discharge criteria: (1) adequate pain control with paracetamol and/or nonsteroidal anti-inflammatory drugs, (2) ability to tolerate solid food, (3) absence of nausea, (4) passage of first flatus and/or first stool, (5) mobilization as preoperative, and (6) acceptance of discharge by the patient.
Study II:Validation of composite outcome for colonic transit recovery
The clinical parameters identified in study I were validated in a second study, that is, the main LAFA trial that contained patients of study I. This was a 9-center (9 Dutch hospitals: 3 University hospitals and 6 teaching hospitals) randomized trial comparing fast-track or standard care in patients undergoing conventional and laparoscopic segmental resection for colon cancer (registration NTR number: NTR222). 14 In study II, after excluding the patients that participated in study I, we evaluated whether the clinical parameters identified in study I indeed best detected differences between the 4 treatment arms. Patient and baseline characteristics were similar to the patients of study I and are shown in Supplementary Table 1 (Supplemental Digital Content 1, http://links.lww.com/SLA/A395). Subsequently, we merged all patients (n = 320) and analyzed whether the clinical hallmarks independently predicted enhanced recovery (ie, shorter length of hospital stay).
Statistical Analysis
Categorical variables are expressed as number and/or percentage of patients. Continuous data are estimated as mean (SD) or as median and interquartile range (IQR) for nonnormally distributed data. Differences between groups were assessed using the 2-tailed Fisher exact test or the χ 2 test for categorical variables and using the Students t test for continuous data with normal distribution. For nonnormally distributed data, the Mann-Whitney U test was used. Kaplan-Meier survivorship curves were generated for the geometrical center (GC) ≥ 2 and the GC < 2 subgroup with the end point "ready for discharge." The positive predictive values (PPVs) of the clinical outcome parameters to predict recovery of GI transit was calculated as the number of patients with recovery of transit and the clinical parameter divided by the number of patients presenting with the clinical parameter. To evaluate the discriminatory ability of the different clinical parameters to correctly pick up patients with and without recovery of colonic transit, receiver operating characteristic (ROC) curves were utilized to display the trade-off between the true positive rate (sensitivity) and false positive rate (1-specificity) and assess the area under the ROC curve as a measure of inherent validity of the different parameters. See supplementary data for the statistical methods of study II (Supplemental Digital Content 2, http://links.lww .com/SLA/A394). A 2-tailed P < 0.05 was considered to be statistically significant. Statistical analysis was performed using SPSS for Windows version 17 (SPSS Inc, Chicago, IL).
RESULTS
Study I: Identification of clinical outcome measures indicative of recovery of GI transit
Patient Characteristics
Of the 95 patients enrolled, 11 patients discontinued, leaving 84 patients for analysis ( Fig. 2 ). Gastric emptying was analyzed in 75 patients on postoperative day 1, as 3 patients were not able to ingest the pancake because of nausea and vomiting. In addition, gastric emptying could not be measured in another 6 patients because of technical or logistic problems (eg no availability of the gamma cameras to scan the patient). Data on colonic transit at day 2 or 3 were available in respectively 77 and 76 patients. The mean patient age was 64.3 years, and the majority of patients (58%) were male (Table 1 ).
GI transit in Patients with Paralytic ileus
In 7 of the 84 patients, the radiolabel had not reached the colon on day 3 (GC = 0). These patients had developed a paralytic ileus resulting from a major surgical complication (internal herniations, adhesions, anastomotic leaks and intraperitoneal bleeding). There was no clear relationship between bowel sounds and the development of paralytic ileus, as in 6 of the 7 patients bowel sounds were still recorded during the first 3 days. In contrast, all patients required reinsertion of a nasogastric tube during the first 3 days (because of abdominal distension, nausea and emesis after having started a liquid diet). In these patients there was an increased length of stay [median 21.8 days (IQR, 17.9-23.9) compared with patients that not developed a paralytic ileus (5.8 (4.0-7.0))]. Moreover, only 5 of the 77 patients in whom the tracer did reach the colon required reinsertion of a nasogastric tube on day 3. Thus, the reinsertion of a nasogastric tube during the early postoperative period is strongly associated with the development of paralytic ileus and postoperative complications.
GI transit in Patients Without Paralytic Ileus
Gastric emptying was analyzed in 69 out of 77 patients on postoperative day 1. The median residual gastric content 2 hours after ingestion of the pancake was 59.4% (IQR, 30.8-93.0), varying from almost complete emptying to complete gastric stasis.
The total amount of 111 In-DTPA (diethylene triamine penta acetate) tracer ingested had reached the colon in all but 3 patients on day 3. The mean calculated GC of activity on day 2 was 1.6 (SD, 0.6; n = 71) and increased to 1.9 (SD, 0.7; n = 69) on day 3. As shown in Figure 1B , patients with a GC between 0 and 1 at day 2 are at risk to have a prolonged hospital stay. Moreover, if GC on day 3 is below 1.5, these patients can only be discharged after more than 7 days, compared to before day 4 if GC is above 1.5. Calculation of the correlation between GC and time to ready for discharge indeed shows a significant correlation of −0.59 (Spearman rank correlation (ρ), P < 0.001, n = 69).
Defecation of radiolabeled material was also assessed as indirect marker of recovery of transit. By day 2, 27% of the patients had defecated radioactivity whereas at day 3, 57% of patients had defecated radiolabeled material. At day 3 the median percentage of 111 In-DTPA tracer defecated in all 67 patients was 19% (IQR, 0-64) of the total ingested radioactive tracer at day 3. Similar to GC, the amount of Indium tracer defecated correlated significantly with time to ready for discharge (ρ = −0.45, P < 0.001, n = 67). In contrast, the residual gastric content of the radiolabeled pancake did not correlate with time until ready for discharge (ρ = 0.12, P = 0.300, n = 75).
Scintigraphic Definition of "Recovery" of GI Transit
In order to identify symptoms associated with recovery of GI transit, we first objectively defined "recovery" of GI transit. To this end, we determined the most optimal cut-off value of colonic transit for predicting whether patients had evacuated radiolabeled material at day 3. The cut-off level was determined using a receiver operating characteristic curve (ROC) that differentiated patients with and without defecation of radioactivity at day 3. As shown in supplementary Figure 1 (Supplemental Digital Content 3, http://links.lww.com/SLA/A393), a cut-off GC value of 2 at day 3 was most optimal in predicting whether patients had evacuated radioactivity (sensitivity 88%, specificity 86%) and thus indirectly recovery of GI transit. To evaluate the reliability of GC ≥2 as marker of recovery of GI transit, evacuation of radiolabeled material was compared in patients with a GC < or ≥ 2 at day 3. Only 8 out of 37 patients with a GC <2 had evacuated radioactivity. In contrast, 31 out of the 32 patients with GC ≥2 had passed 66% (IQR, 39-91) of the radiolabel into the stool at day 3.
In the same line, if GC ≥2 is a good marker of recovery of GI transit, patients with a GC ≥2 should have better clinical outcome. Indeed, the median time until ready for discharge ( Fig. 3A) , the time until first defecation (D), tolerance of solid food (SF) and time until patients had had tolerance of solid food and had had defecation (SF + D) were all significantly shorter in patients with GC ≥ 2 or "recovery of GI transit" at day 3 (Fig. 3B) . In contrast, time to first flatus was not different between the 2 groups.
FIGURE 3.
A, Kaplan-Meier curve of time until ready for discharge. Kaplan-Meier estimate of the time until ready for discharge for patient with GC ≥ 2 and for patients with GC < 2 at day 3. Patients with GC ≥ 2 (n = 32) were significantly faster ready for discharge (median of 2.0 days) than those with a GC < 2 (n = 37). B, clinical parameters vs recovery colonic transit. Time to first flatus, first defecation (D), first tolerance of solid food (SF), and time until patients tolerate solid food and passed stool (SF + D) in patients with GC ≥2 (n = 32) and patients with GC <2 (n = 37). Data are shown as median, IQR. The Mann-Whitney U test was used to compare the 2 groups. P < 0.05 was considered statistically significant. NS indicates nonsignificant.
Identification of Clinical Parameters Indicative of Recovery of Colonic Transit
Subsequently, we assessed which clinical parameters best identified patients with recovery of GI transit and thus represent the most optimal clinical outcome measure. To this end, ROC curves of clinical outcome measures were calculated for discriminating patients with a GC < or ≥ 2. The diagnostic capacity of a clinical outcome parameter to identify recovery of GI transit was determined by calculating the corresponding area under the ROC curve (AUC values). Due to missing data on colonic transit, the overall analysis of data for identification of clinical parameters indicative of recovery of colonic transit was conducted in 72 patients. Results on colonic transit were available in 71 and 69 patients at day 2 and 3 postoperatively.
As shown in Figure 4 , the time to passing stool, or the time to tolerance of solid food had high accuracy for identifying patients with a GC ≥2 at day 3 (AUC, respectively, 0.77 and 0.81). The AUC for the time until patients had had SF + D was 0.87 (SE 0.04, 95% CI = 0.79-0.95, P < 0.001) (Fig. 4) . The time to first flatus was not a significant discriminator to identify recovery (P = 0.467). Similar to day 3, the largest AUC discriminating patients with recovery of GI transit at day 2 was provided by the model incorporating SF + D (AUC 0.85 ± 0.05 (95% CI = 0.75-0.95, P < 0.001) (Fig. 4) .
In addition, we evaluated whether the composite outcome SF + D was useful to indicate if a patient had recovery of GI transit on the ward. Therefore, we calculated the PPVs of the clinical outcome parameters to predict recovery of GI transit. Passing flatus on or before day 2 had a PPV of 48% (95% CI = 34-62). In contrast, the PPV of defecation or of tolerating solid food on or before day 2 was 71% (95% CI = 52-86) and 58% (95% CI = 39-57) respectively. If patients had had SF + D on day 2, GI transit was recovered in 88% (95% CI = 64-99). The PPVs of the clinical outcome measures reported on day 3 increased to 76%, 85%, and 89% for, respectively, flatus, stool, and tolerance of solid food, compared to 93% (95% CI = 78-99) for SF + D.
Study II: Validation of Composite Outcome for Colonic Transit Recovery
We validated the composite outcome SF + D in 320 patients who participated in a large randomized surgical trial (LAFA trial) in which laparoscopic and open surgery were compared in patients undergoing standard or fast-track perioperative care. 12 To this end, we evaluated SF + D as outcome parameter for detecting differences between the 4 treatment arms. In line with previous reports on GI motility and transit, 3, 13, 15, 16 the time to SF + D was significantly shorter after laparoscopy and fast-track care (Fig. 5 ). In contrast, as published by Vlug et al, 12 no statistically significant difference between the laparoscopy and open groups was detected by the traditional indicators of return of bowel activity: time to first flatus, time to first defecation, or time to tolerance of solid food. Moreover, when all 320 patients were merged, multiple regression analysis revealed that achieving SF + D leads to a reduction of 43% (95% CI = 35-48) in length of stay and best predicted hospital stay (Supplementary Table 2 , Supplemental Digital Content 4, http://links.lww.com/SLA/ A396).
DISCUSSION
To date, there is no consensus on the most clinically meaningful hallmark assessing recovery of GI motility after abdominal surgery. 2, 17, 18 The time to return of bowel sounds and time to first passage of flatus have been commonly referred to as indicators of bowel activity, notwithstanding the fact that these parameters are subjective and time-dependent measures. 19, 20 Here, we objectively determined colonic transit using scintigraphy and showed that clinical recovery after abdominal surgery is indeed associated with recovery of colonic transit. Using the latter as objective criterion for clinical improvement, we showed that tolerance of solid food and having had defecation (SF + D) best predicted clinical recovery and length of hospital stay. In contrast, time to first flatus was not associated with recovery of colonic transit or time to discharge. On the basis of these findings, we propose that the time to SF + D is the best objective parameter to assess clinical recovery and readiness to be discharged and should preferentially be used to determine the duration of POI in future clinical trials.
In the first part of this study, we aimed to study the relationship between clinical symptoms and recovery of GI transit. To this end, 84 patients ingested a 99m Tc-labeled pancake and 100 mL of 111 In-labeled water 24 hours after intestinal surgery to assess gastric emptying and colonic transit. Gastric emptying measured on day 1 largely varied from complete gastric stasis to almost complete emptying and most importantly was not associated with clinical recovery, defined as time until ready for discharge. On the contrary, colonic transit measured as the geometric center of radioactivity correlated with the time to defecation of radiolabeled material and was significantly correlated with time to ready for discharge, indicating that recovery of colonic transit is indeed an important determinant of clinical recovery after abdominal surgery. In a next step, we used "recovery of colonic transit," defined as a GC ≥2, to identify the clinical symptoms that best correlated with clinical recovery. Using ROC curve analysis, we observed that the clinical parameters passing stool and tolerance of solid food had a high accuracy for identifying patients with recovery of GI transit with an AUC of, respectively, 0.77 and 0.81 and a PPV of 85% and 89%, respectively. Moreover, when both parameters were present, that is, patients tolerated solid food and had defecated, the AUC further increased to 0.87 with a PPV of 93%. The PPV for passing flatus was only 76%, indicating that this clinical parameter is a poor predictor of clinical recovery. In line with our findings, manometric studies evaluating the relationship between clinical parameters and recovery of GI motility also reported that the restoration of intestinal motility does not coincide with the first passage of flatus. In fact, bowel sounds and the first passage of flatus occurred later than the restoration of migrating motor complexes in the proximal jejunum. 21, 22 This contradiction between the resolution of small intestinal motility disturbances and the first passage of flatus and stool may be related to the more prolonged ileus of the colon in the postoperative period. 22 Recovery of small bowel motility indeed takes place within hours of operation, followed by return of gastric function within 1 to 2 days, whereas colonic function may require 2 to 5 days to recover. 23, 24 Taken together, our data indicate that the presence SF + D is the most reliable parameter indicating recovery of colonic transit, and thus it could be useful to assess clinical recovery after abdominal surgery. Correspondingly, using the outcome parameter SF + D, we were able to detect significant differences between the laparoscopy and open groups in the multicenter LAFA trial. In this large randomized trial, a significantly shorter hospital stay has been reported after laparoscopy and fast-track care, with no difference between the laparoscopy and open groups for traditional indicators of return of bowel function such as time to first flatus. 12 Moreover, when all 320 patients were merged, multiple regression analysis revealed that SF + D best predicted hospital stay. These data confirm that SF + D indeed best reflects GI transit as well as clinical recovery, and are in line with a recent proposal promoting the composite end point SF + D as a more robust and appropriate endpoint because it is subject to considerable less variability compared to the composite endpoint incorporating time to first flatus. Ludwig et al 25 used a composite assessment that measured upper (toleration of solid food) and lower (first defecation) GI tract recovery, with time to resolution of POI based on the last event to occur. As the time to first flatus may be a less objective end point than time to first defecation because a patient must be conscious and willing to report it, 20 the composite end point SF + D was advocated to be a more appropriate measure of GI tract recovery in the bowel resection population. 25 However, in contrast to our study, this conclusion was not supported by objective observational data of recovery of GI motility but proposed after studying the variability of different endpoints. The implication of this composite endpoint for clinical routine is that it may help the clinician to decide which patients are ready for discharge.
The current study had several limitations. The analyses examining SF + D as an independent variable in predicting readiness for hospital discharge could be confounded by the fact that these same clinical parameters (ability to tolerate solid food, passage of stool) were being considered in the decision to regard the patient as suitable for discharge. Another limitation is that gastric emptying of the radiolabeled pancake was only assessed on day 1. At this time point, motility in general may still be significantly affected by the anesthetics and analgesics used, and it is therefore of no surprise that gastric emptying on day 1 is not associated with clinical recovery. In addition, an extended gastric emptying scintigraphy test from 2 to 4 hours may have been more sensitive in detecting patients with gastroparesis. 26 Nevertheless, the strength of our study is the objective measurement of motility by assessment of GI transit in a large cohort of segmental colectomy patients, and the subsequent validation of the clinical hallmark indicating recovery of bowel function in the patients of the main multicenter trial. To what extent our findings can be extrapolated to all types of surgical procedures warrants further investigation.
CONCLUSIONS
Our study demonstrates that the presence of SF + D best reflects recovery of GI transit and indicates readiness for discharge. These data provide objective evidence that the presence of both clinical parameters is the best clinical marker of gut recovery and is to be preferred as primary outcome measure in future clinical trials on POI.
